---
title: "Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293341740.md"
description: "On July 21, 2026, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a leading biotech firm, shared their accomplishments and future goals for 2026. The company specializes in advanced genetic therapies."
datetime: "2026-07-21T12:10:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293341740.md)
  - [en](https://longbridge.com/en/news/293341740.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293341740.md)
generator: "portal-rs"
---

# Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

On July 21, 2026, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a leading biotech firm, shared their accomplishments and future goals for 2026. The company specializes in advanced genetic therapies.

### Related Stocks

- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)

## Related News & Research

- [Circio boosts circVec gene therapy data and secures funding runway to 2030](https://longbridge.com/en/news/297552739.md)
- [09:11 ETBioViva Announces U.S. Patent for Klotho Gene Therapy Targeting Age-Related Cognitive Decline](https://longbridge.com/en/news/297657999.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)
- [Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports](https://longbridge.com/en/news/297596287.md)
- [Kala Bio signs LOI for exclusive US distribution of Virotek ophthalmology genetic tests](https://longbridge.com/en/news/297646733.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**